Arctigenin

Drug Profile

Arctigenin

Alternative Names: Arctium lappa extract; ARG; Burdock fruit extract; GBS-01

Latest Information Update: 12 Oct 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator National Cancer Center (Tokyo)
  • Developer Kracie Pharma; National Cancer Center (Tokyo); Toyama Medical and Pharmaceutical University
  • Class Antineoplastics
  • Mechanism of Action Apoptosis stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Pancreatic cancer

Most Recent Events

  • 03 Oct 2016 National Cancer Center Hospital East and Kracie Pharma completes a phase II trial in Pancreatic cancer (Late-stage disease, Second-line therapy or greater) in Japan (UMIN000010111)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top